Search tips
Search criteria 


Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
AAPS PharmSciTech. 2002 September; 3(3): 39–46.
Published online 2015 February 19. doi:  10.1007/BF02830619
PMCID: PMC2784050

A study of the antiresorptive activity of salmon calcitonin microspheres using cultured osteoclastic cells


The purpose of this study was to evaluate salmon calcitonin (sCT) microspheres in vitro for their antiresorptive activity using cultured osteoclastic cells. The antiresorptive activity of sCT-loaded microspheres, prepared from a low molecular weight hydrophilic poly (lactide-co-glycolide) polymer (PLGA), was studied using bone marrow culture cells harvested from juvenile rats and cultured on silces of devitalized bone for up to 4 weeks. The resorptive activity of osteoclastic cells was quantified in terms of number and type of resorption pits and total area of resorption. Microspheres containing 5.1% sCT released 70% peptide in 2 weeks and 88% in 4 weeks. All sCT treatments inhibited total resorptive activity. A dose-dependent decrease in resorption was observed with sCT microspheres at 2 weeks. The high dose (10 mg of microspheres) produced a 99.5% decrease in resorption at 3 weeks, while the low dose (1 mg) produced an 80% reduction. Exposure of cultures to soluble sCT and sCT-loaded microspheres caused a decrease in the number of large pits, which were the predominant type formed in control cultures. Thus, this system could serve as an in vitro method to evaluate the antiresorptive effect of PLGA-sCT microspheres.

Key words: Salmon calcitonin (sCT), poly (lactide-coglycolide) polymer (PLGA) microspheres, cell culture, osteoclasts, bone resorption

Full Text

The Full Text of this article is available as a PDF (355K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Chambers TJ, Moore A. The sensitivity of isolated osteoclasts to morphological transformation by calcitonin. J Clin Endocrinol Metab. 1983;57:819–824. doi: 10.1210/jcem-57-4-819. [PubMed] [Cross Ref]
2. Milhaud G. Etude du mecanisme de l'action hypocalcemiante de la thyrocalcitonine. CR Acad Sci Paris. 1965;261:813–816. [PubMed]
3. Martin TJ, Robinson CJ, Maclntyre I. The mode of action of thyrocalcitonin. Lancet. 1966;1:900–902. doi: 10.1016/S0140-6736(66)91577-7. [PubMed] [Cross Ref]
4. Kohler H. Wechselwirkung von Thyreocalcitonin und Parathormon. Schweiz med Wochenschr. 1968;98:728–728. [PubMed]
5. Munson PL. Physiology and pharmacology of thyrocalcitonin. In: Aurbach GD, editor. Handbook of Physiology. Washington, DC: American Physiological Society; 1976. pp. 443–464.
6. Huwyler R, Born W, Ohnhaus EE, Fischer JA. Plasma kinetics and urinary excretion of exogenous human and salmon calcitonin in man. Am J Physiol. 1979;236:E15–E19. [PubMed]
7. Millest AJ, Evans JR, Young JJ, Johnstone D. Sustained release of salmon calcitonin in vivo from lactide: glycolide copolymer depots. Calcif Tissue Int. 1993;52:361–364. doi: 10.1007/BF00310200. [PubMed] [Cross Ref]
8. Lee KC, Soltis EE, Newman PS, Burton KW, Mehta RC. DeLuca PP. In vivo assessment of salmon calcitonin sustained release from biodegradable microspheres. Control Release. 1991;17:199–206. doi: 10.1016/0168-3659(91)90059-M. [Cross Ref]
9. Nichols KG, Puleo DA. Effect of metal ions on the formation and function of osteoclastic cells. J Biomed Mater Res. 1997;35:265–271. doi: 10.1002/(SICI)1097-4636(199705)35:2<265::AID-JBM14>3.0.CO;2-G. [PubMed] [Cross Ref]
10. Dani BA, DeLuca PP. Preparation, characterization and in vivo evaluation of salmon calcitonin microspheres. AAPS Pharm Sci Tech. 2001; 2(4):Aritcle [] [PMC free article] [PubMed]
11. Malik MA, Puleo DA, Bizios R, Doremus RH. Osteoblasts on hydroxylapatite, bone and alumina in vitro: morphology during the first two hours of attachment. Biomaterials. 1992;13:123–128. doi: 10.1016/0142-9612(92)90008-C. [PubMed] [Cross Ref]
12. Puleo DA, Huh WW. Acute toxicity of metal ions in cultures of osteogenic cells derived from bone marrow stromal cells. J Appl Biomater. 1995;6:109–116. doi: 10.1002/jab.770060205. [PubMed] [Cross Ref]
13. Nijweide PJ, Burger EH, Feyer JM. Cells of Bone: Proliferation, differentiation and hormonal regulation. Physiol Rev. 1986;66:885–886. [PubMed]
14. Sugawara K, Hamada M, Hosoi S, Tamaoki T. A useful method to evaluate bone resorption inhibitors using osteoclast-like multinucleated cells. Anal Biochem. 1998;255:204–210. doi: 10.1006/abio.1997.2474. [PubMed] [Cross Ref]
15. Scheven BA, Kanilarange-de-Haas EM, Wassenaar AM, Nikweide PJ. Differentiation kinetics of osteoclasts in periosteum of embryonic bones in vivo and in vitro. Anat Rec. 1986;214:418–423. doi: 10.1002/ar.1092140413. [PubMed] [Cross Ref]
16. Prallet B, Male P, Neff L, Baron R. Identification of functional mononuclear precursors of the osteoclast in chicken medullary. J Bone Miner Res. 1992;7:405–414. doi: 10.1002/jbmr.5650070408. [PubMed] [Cross Ref]

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists